MYeloma Resistance And Clonal Evolution (MYRACLE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03807128 |
Recruitment Status :
Recruiting
First Posted : January 16, 2019
Last Update Posted : August 6, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Multiple Myeloma | Other: No interventional study |
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 1400 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 10 Years |
Official Title: | MYeloma Resistance And Clonal Evolution |
Actual Study Start Date : | February 11, 2019 |
Estimated Primary Completion Date : | February 11, 2029 |
Estimated Study Completion Date : | February 11, 2029 |
- Other: No interventional study
No interventional study
- Describe the mechanisms of resistance of myeloma cells. [ Time Frame: Ten years ]Number of resistance.
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
The study population corresponds to multiple myeloma patients managed in the hematology departments of the University Hospital of Nantes and the CHD of La Roche sur Yon.
Recruitment of the hematology departments of the University Hospital of Nantes and CHD of La Roche sur Yon makes it possible to envisage an annual recruitment of 60 new myeloma diagnoses, and an annual number of 80 relapses. These data are estimated from the number of files submitted to the Multidisciplinary Collaborative Meeting (RPN) and the annual inclusion number in clinical trials. This number represents a cohort of about 140 inclusions per year. The average number of visits can be estimated at 1.5 / year per patient.
Inclusion Criteria:
- Patient with diagnosis of multiple myeloma according to standard criteria
- Age >18
Exclusion Criteria:
- Minor patient
- Patient under guardianship
- Protected patient
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03807128
Contact: Cyrille TOUZEAU, PU | 02 40 08 32 71 | cyrille.touzeau@chu-nantes.fr |
France | |
La Roche sur Yon Hospital Departmental | Recruiting |
La Roche-sur-Yon, France, 85000 | |
Nantes University Hospital | Recruiting |
Nantes, France, 44093 | |
Contact: Cyrille TOUZEAU, PU 02 53 48 24 05 cyrille.touzeau@chu-nantes.fr |
Principal Investigator: | Cyrille TOUZEAU, PU | Nantes University Hospital |
Responsible Party: | Nantes University Hospital |
ClinicalTrials.gov Identifier: | NCT03807128 |
Other Study ID Numbers: |
RC18_0197 |
First Posted: | January 16, 2019 Key Record Dates |
Last Update Posted: | August 6, 2021 |
Last Verified: | August 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Myeloma Cohort Resistance Quality of life |
Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases |
Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases |